Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Alper, US
Chester A. Alper, Brookline, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090142355 | DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES - Methods for the diagnosis and treatment of type 1 diabetes are described. HLA-DQA2 has now been identified as the gene which is primarily responsible for determining whether an individual is susceptible to develop type 1 diabetes. The use of HLA-DQA2 as a target for developing therapeutic and diagnostic targets for treating type 1 diabetes and detecting susceptibility for the disease is disclosed. | 06-04-2009 |
Edward A. Alper, Houston, TX US
| Patent application number | Description | Published |
|---|---|---|
| 20090017134 | METHOD FOR CONTROLLING FIRE ANTS - A method for controlling fire ants is described, which includes applying a silver-containing composition to an area infested by fire ants or threatened by an infestation. The composition is applied to the area and reduces or eliminates the colony within a period of about two to four weeks and prevents fire ant re-infestation for a period of about six months to one year. | 01-15-2009 |
Hal Alper, Flowery Branch, GA US
| Patent application number | Description | Published |
|---|---|---|
| 20080210635 | Process and system for removal of contaminants from industrial streams - A method and system for removing from an aqueous system which is contaminated therewith: (1) mercury present as colloids, ions and/or organically bound compounds, and (2) hydrocarbons solubilized, dispersed, and/or emulsified in the said system. Pursuant to the invention the aqueous system to be treated (such as “produced water”) is passed successively through three filtration stages. The first filtration stage is provided with absorption media which effects reduction/removal of dispersed organically bound mercury species and of the dispersed and partially dissolved hydrocarbon phases, as well as of some colloidal mercury and other dissolved metallic species. The second filtration stage utilizes a salt modified reticulated granular filtration media for reduction/removal of slightly dissolved hydrocarbon phases, mercury in colloidal and ionic form and other dissolved metals. The third filtration stage is a polishing stage, which serves to further reduce by electroless or voltaic reduction residual elemental mercury and/or residual colloidal and ionic mercury. At this third stage metallic mercury is incorporated into a metallic matrix from which the mercury may preferably be recovered. | 09-04-2008 |
| 20090139918 | Visual bilgewater quality indicator - A visual bilgewater quality indicator for use in a bilgewater filtration system which includes a filtration stage for removing oily contaminants. The quality indicator utilizes one or more filtration status chambers which are provided with a fluorescent or phosphorescent dye or pigment treated filtration media. The status chamber has a transparent outer wall. Flow through the status chamber is from the outer lateral wall toward its central axis, whereby oily contaminants in the flow collect selectively at the outer portions of the filtration media which are highly visible to an observer. Oil droplets as small as one micron, are captured and immobilized by the primary filter and are instantly visible against the background of the exemplary dye. If two status chambers are used in series, due to the ability of the infused media to permanently capture oil without re-entrainment, the second chamber is always kept transparent until complete loading and supersaturating breakthrough at the primary chamber. Oily droplet visibility can be further enhanced with ultraviolet illumination. | 06-04-2009 |
| 20100000409 | Process and system for separating finely aerosolized elemental mercury from gaseous streams - A method and apparatus for practicing the method are provided for separating droplets of finely aerosolized elemental mercury from a gaseous stream in which the droplets are dispersed. In the method a gold plated metallic capillary surface is contacted with the gaseous stream, causing the aerosolized droplets to deposit on the capillary surface and by capillary action to coalesce with other of such droplets to form increasingly large drops of mercury. The surface is oriented to allow the mercury to flow by gravitational forces and capillary action to the lowermost portions of the surface, at which it accumulates, and is then collected at a suitable vessel. | 01-07-2010 |
| 20110198276 | SYSTEM FOR REMOVAL OF CONTAMINANTS FROM INDUSTRIAL STREAMS - A method and system for removing from an aqueous system which is contaminated therewith: (1) mercury present as colloids, ions and/or organically bound compounds, and (2) hydrocarbons solubilized, dispersed, and/or emulsified in the said system. Pursuant to the invention the aqueous system to be treated (such as “produced water”)is passed successively through three filtration stages. The first filtration stage is provided with absorption media which effects reduction/removal of dispersed organically bound mercury species and of the dispersed and partially dissolved hydrocarbon phases, as well as of some colloidal mercury and other dissolved metallic species. The second filtration stage utilizes a salt modified reticulated granular filtration media for reduction/removal of slightly dissolved hydrocarbon phases, mercury in colloidal and ionic form and other dissolved metals. The third filtration stage is a polishing stage, which serves to further reduce by electroless or voltaic reduction residual elemental mercury and/or residual colloidal and ionic mercury. At this third stage metallic mercury is incorporated into a metallic matrix from which the mercury may preferably be recovered. | 08-18-2011 |
Hal S. Alper, Cambridge, TX US
| Patent application number | Description | Published |
|---|---|---|
| 20100291648 | Global transcription machinery engineering - The invention relates to global transcription machinery engineering to produce altered cells having improved phenotypes. | 11-18-2010 |
Hal S. Alper, Austin, TX US
| Patent application number | Description | Published |
|---|---|---|
| 20100330614 | GLOBAL TRANSCRIPTION MACHINERY ENGINEERING TARGETING THE RNAP ALPHA SUBUNIT (RPOA) - The invention relates to global transcription machinery engineering to produce altered cells having improved phenotypes. | 12-30-2010 |
Mark D. Alper, Mukwonago, WI US
| Patent application number | Description | Published |
|---|---|---|
| 20100249313 | High Styrene SBS Hot Melt Adhesive - Multipurpose hot melt adhesive compositions which are suitable for use as both a construction and elastic attachment adhesive for disposable soft goods, such as disposable diapers, feminine sanitary napkins, surgical drapes, hospital pads, and adult incontinent products. The multipurpose hot melt adhesive compositions have a high level of creep resistance, high bond strength, and relatively low viscosity, and are composed of endblock resin in combination with a linear styrene-butadiene-styrene (SBS) copolymer wherein the copolymer has a styrene content greater than about 35% by weight, and preferably about 38% to about 50% by weight. | 09-30-2010 |
| 20110021103 | Hot Melt Adhesive Based on Olefin Block Copolymers - A hot melt adhesive composition, comprising a blend of components including about 5% to about 50% by weight of an olefin block copolymer; about 10% to about 70% by weight of a first tackifying resin having a softening point of at least about 95° C.; about 0 to 65% of a second tackifying resin that is different than the first tackifying resin; about 0% to about 60% by weight of a plasticizer; about 0% to about 20% by weight of an aromatic reinforcing resin having a softening point equal to or higher than 115° C.; about 0.1% to about 5% by weight of a stabilizer; and about 1% to about 40% by weight of a secondary polymer that is different from the olefin block copolymer, the first and second tackifying resins and the reinforcing resin, having relatively low crystallinity, which low crystallinity is equal to or less than 250 Joules/gram, wherein the components total 100% by weight of the composition, and the viscosity of the composition is equal to or less than about 20,000 mPa·s at 163° C. Laminates, especially those used in disposable soft goods, and methods of making such laminates using the hot melt adhesive composition are also described. The adhesive composition and/or laminate may be used in making a variety of end products such as a disposable diaper, a sanitary napkin, a bed pad, a bandage, a surgical drape, a tape, a label, a plastic sheet, a nonwoven sheet, a paper sheet, a cardboard, a book, a filter, or a package. | 01-27-2011 |
Ozge Alper US
| Patent application number | Description | Published |
|---|---|---|
| 20080293162 | Methods and compositions for diagnosing neoplastic disease - Methods and compositions for determining whether a subject at least has a neoplastic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a soluble filamin analyte, such as a filamin A analyte, to determine whether the subject at least has the neoplastic disease. Also provided are kits, systems, and devices for practicing the subject methods. | 11-27-2008 |
Ozge Alper, Bethesda, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20100272640 | Monoclonal Antibodies Against PCBP-1 Antigens, and Uses Therefor - The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens. | 10-28-2010 |
| 20110136148 | Monoclonal Antibodies Against GMF-B Antigens, and Uses Therefor - The disclosure relates to monoclonal antibodies (mAbs) preferentially selective for soluble GMF-B (sGMF-B) antigens or for sGMF-B as well as other forms of GMF-B, hybridoma lines that secrete these antibodies or fragments thereof, and the use of such antibodies and antibody fragments to preferentially detect sGMF-B antigens, including for example those expressed by cancer cells or in patients with cancer or dementia. Other aspects of the present disclosure relate to antibodies that are specific to or demonstrate preferential binding to a soluble or secreted form of GMF-B. Yet other aspects relate to antibodies or antibody fragments that are capable of reducing the activity of GMF-B in at least one form, including a soluble form or a secreted form. The present disclosure further relates to monoclonal, chimeric antibodies and fragments thereof, processes for producing such antibodies and their fragments, and their therapeutic and diagnostic uses, including in the treatment and detection of cancer, e.g., human breast, ovary, head, neck, and brain, and dementia. Methods and kits for the immunodetection and immunotherapy of cells or samples which express sGMF-B antigens, e.g., from patient and non-patient samples, are also disclosed. | 06-09-2011 |
Özge Alper, Rockville, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20100330593 | METHODS AND COMPOSITIONS FOR DIAGNOSING NEOPLASTIC DISEASE - Methods and compositions for determining whether a subject at least has a neoplastic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a soluble filamin analyte, such as a filamin A analyte, to determine whether the subject at least has the neoplastic disease. Also provided are kits, systems, and devices for practicing the subject methods. | 12-30-2010 |
Özge Alper, Rockville, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20100330593 | METHODS AND COMPOSITIONS FOR DIAGNOSING NEOPLASTIC DISEASE - Methods and compositions for determining whether a subject at least has a neoplastic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a soluble filamin analyte, such as a filamin A analyte, to determine whether the subject at least has the neoplastic disease. Also provided are kits, systems, and devices for practicing the subject methods. | 12-30-2010 |
Õzge Alper, Bethesda, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20110256056 | Monoclonal Antibodies Against HER2 Antigens, and Uses Therefor - The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express HER2 antigens. | 10-20-2011 |
Paul Alper, Wynnewood, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20110316701 | MONITORING SYSTEM - A group monitoring system for dispenser usage compliance is provided. The system is for a predetermined group of interest in a predetermined facility type. A dispenser data collection system is operably connected to a plurality of dispensers and is capable of providing information. The information includes a unique dispenser identifier and a number of dispenser usage events. The information from the data collection system is received and the predetermined group within which each dispenser is associated is determined. The number of dispenser usage events is determined. A benchmark which corresponds to dispenser usage opportunities particular to the predetermined group and particular to the predetermined time period is determined. The dispenser usage compliance index particular to the predetermined group and particular to the predetermined time period is determined by dividing the dispenser usage events for the predetermined group and the predetermined time period by a denominator which equals the benchmark. | 12-29-2011 |
Phillip Alper, San Diego, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20080242671 | INHIBITORS OF CATHEPSIN S - The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S. | 10-02-2008 |
| 20100204200 | INHIBITORS OF CATHEPSIN S - The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S. More particularly, the present invention provides compounds having Formula 1: | 08-12-2010 |
Phillip B. Alper, Poway, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20110245243 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cathepsin S. | 10-06-2011 |
Phillip B. Alper, San Diego, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090075996 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia. | 03-19-2009 |
| 20090137570 | INHIBITORS OF CATHEPSIN S - The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S. | 05-28-2009 |
| 20090270409 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119. | 10-29-2009 |
| 20100022515 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising compound of following formula (I), and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119 (G protein-coupled receptor 119) such as obesity, diabetes and hyperlipidemia. | 01-28-2010 |
| 20100120807 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119. | 05-13-2010 |
| 20110166176 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119. | 07-07-2011 |
| 20110172244 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, of Formula I: pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119. | 07-14-2011 |
| 20110224185 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119. | 09-15-2011 |
Seth L. Alper, Boston, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090288222 | Transgenic plants overexpressing a plant vacuolar Pyrophosphatase - Transgenic plants are described which are engineered to overexpress vacuolar H | 11-19-2009 |
Sharon A. Alper, Seattle, WA US
| Patent application number | Description | Published |
|---|---|---|
| 20090164345 | System and method for management and control of containerized freight - A system and method for managing containerized freight is disclosed. The system generates a 3-D view of a containerized freight terminal that is rendered on a display. The 3-D view includes rendered scale models of all the containers, vessels, buildings and equipment within the freight yard and according to stored information relating to such. The rendered 3-D view is updated as changes are made to the stored information and according to user input related to the desired point of view and perspective. The rendered scale models may be selectively visually coded or displayed according to pre-determined criteria. | 06-25-2009 |